Mohammad Hosseini-Farid

Dr. Mohammad Hosseini-Farid

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MHMohammad Hosseini-Farid
Mohammad Hosseini-Farid
MAMaryam Amiri
Maryam Amiri
MRMohammadreza Ramzanpour
Mohammadreza Ramzanpour
MZMariusz Ziejewski
Mariusz Ziejewski
Ghodrat KaramiGhodrat Karami
Ghodrat Karami
Knowing the precise material properties of intracranial head organs is crucial for studying the biomechanics of head injury. It has been shown that these biological tissues are significantly rate-dependent; hence, their material properties should be determined with respect to the range of deformation rate they experience. In this paper, a validated finite element human head model is used to investigate the biomechanics of the head in impact and blast, leading to traumatic brain injuries (TBI). We simulate the head under various directions and velocities of impacts, as well as helmeted and unhelmeted head under blast shock waves. It is demonstrated that the strain rates for the brain are in the range of 36 to 241 s−1, approximately 1.9 and 0.86 times the resulting head acceleration under impacts and blast scenarios, respectively. The skull was found to experience a rate in the range of 14 to 182 s−1, approximately 0.7 and 0.43 times the head acceleration corresponding to impact and blast cases. The results of these incident simulations indicate that the strain rates for brainstem and dura mater are respectively in the range of 15 to 338 and 8 to 149 s−1. These findings provide a good insight into characterizing the brain tissue, cranial bone, brainstem and dura mater, and also selecting material properties in advance for computational dynamical studies of the human head.

14 October 2019 in Biomechanics and Modeling in Mechanobiology
Verified
Journal Article
Closed access
PDF file
MHMohammad Hosseini-Farid
Mohammad Hosseini-Farid
MRMohammadreza Ramzanpour
Mohammadreza Ramzanpour
JMJayse McLean
Jayse McLean
MZMariusz Ziejewski
Mariusz Ziejewski
Ghodrat KaramiGhodrat Karami
Ghodrat Karami

18 November 2019 in Journal of Vibration and Acoustics
Verified
Journal Article
Closed access
PDF file
AEAshkan Eslaminejad
Ashkan Eslaminejad
MHMohammad Hosseini-Farid
Mohammad Hosseini-Farid
MZMariusz Ziejewski
Mariusz Ziejewski
Ghodrat KaramiGhodrat Karami
Ghodrat Karami
In this paper, we identified the material constitutive parameters of the human skull from reported tensile test results. Initially, we applied both linear-elastic and Mooney–Rivlin nonlinear hyperelastic constitutive models to the available tensile test data at different strain rates of 0.005, 0.10, 10, and 150 1/sec. It was shown that the suggested hyperelastic model fitted the test results with higher accuracy in comparison with the linear-elastic model. In the next step, the experimental modal analysis was carried out through roving hammer-impact tests on a dried human skull. The first four natural frequencies of the skull were measured to be 496, 543, 1250, and 1287 Hz, and these values were verified by the modal assurance criterion. Then, a 3D finite element (FE) model of that human skull was created by a 3D scanner and discretized to carry out a computational modal analysis. The performance of the determined material properties for the human skull from both linear and hyperelastic material models was evaluated using FE modal analysis. The calculated modal frequencies were then compared to the experimentally measured frequencies. It was shown that the material parameters from both the linear and hyperelastic constitutive models obtained at a strain rate of 0.10 1/sec, provided the best performance in computational modal analysis with minimum deviations relative to the experimental results. These results confer a better understanding of the human skull behavior among different strain rates, which could increase the accuracy of nonlinearity dynamic simulations on the skull.

1 March 2022 in Journal of Engineering and Science in Medical Diagnostics and Therapy
Verified
Journal Article
Closed access
PDF file
MRMohammadreza Ramzanpour
Mohammadreza Ramzanpour
MHMohammad Hosseini-Farid
Mohammad Hosseini-Farid
MZMariusz Ziejewski
Mariusz Ziejewski
Ghodrat KaramiGhodrat Karami
Ghodrat Karami

4 September 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
M. Marc AbreuM. Marc Abreu
M. Marc Abreu
MHMohammad Hosseini-Farid
Mohammad Hosseini-Farid
DSDavid G Silverman
David G Silverman
Background: Neurological disorders are the leading cause of disability, affecting over three billion people. Amyotrophic lateral sclerosis (ALS) is among the most feared and uniformly fatal neurodegenerative diseases, with no therapy capable of restoring function. Methods: We report the first application of therapeutic fever to ALS using Computerized Brain-Guided Intelligent Thermofebrile Therapy (CBIT²). This fully noninvasive treatment, delivered through FDA-approved computerized platform, digitally reengineers the 1927 Nobel Prize–recognized malarial fever therapy into a modern treatment guided by the Brain–Eyelid Thermoregulatory Tunnel. CBIT² induces therapeutic fever through synchronized hypothalamic feedback, activating heat shock proteins to restore proteostasis and neuronal function. Case presentation: A 56-year-old woman with rapidly progressive ALS was diagnosed at the Mayo Clinic, based on electromyography showing denervation and fasciculations corroborated by neurological and MRI findings; and patient was informed of an expected 3–5-year survival. Northwestern University independently confirmed the diagnosis and maintained her on FDA-approved ALS drugs (riluzole and edaravone). Her condition worsened and she underwent CBIT², resulting in: (i) electrophysiological reversal with disappearance of denervation and fasciculations; (ii) biomarker correction, including reductions in neurofilament and homocysteine, besides IL-10 normalization (previously linked to mortality) alongside robust HSP70 induction; (iii) restoration of gait, swallowing, respiration, speech, and cognition; and (iv) return to complex motor tasks, including golf and pickleball. Discussion/Conclusion: This case provides the first documented evidence that ALS can be reversed through digitally reengineered fever therapy aligned with thermoregulation. Beyond ALS, shared protein-misfolding pathology suggests CBIT² may extend to Alzheimer’s, Parkinson’s, and related disorders. By modernizing a Nobel Prize–recognized therapeutic principle with digital precision, CBIT² establishes a framework for large-scale clinical trials. Just as fever therapy a century ago restored lost brain function in dementia paralytica and earned the 1927 Nobel Prize, CBIT² now safely harnesses the therapeutic power of fever through brain-guided modulation. Amid a global brain health crisis, where neurological disorders affect more than three billion people, fever-based therapies may provide a path to preserve thought, memory, movement, and independence for over one third of humanity.

12 November 2025 in Diseases
Verified
Journal Article
Open access
PDF file
M. Marc AbreuM. Marc Abreu
M. Marc Abreu
MHMohammad Hosseini-Farid
Mohammad Hosseini-Farid
DSDavid G Silverman
David G Silverman
Background: Neurological disorders are the leading cause of disability, affecting over three billion people worldwide. Amyotrophic lateral sclerosis (ALS) is among the most feared and uniformly fatal neurodegenerative diseases, with no therapy capable of restoring lost function. Methods: We report the first application of therapeutic fever to ALS using Computerized Brain-Guided Intelligent Thermofebrile Therapy (CBIT2). This fully noninvasive treatment, delivered through an FDA-approved computerized platform, digitally reengineers the 1927 Nobel Prize-recognized malarial fever therapy into a modern treatment guided by the Brain–Eyelid Thermoregulatory Tunnel. CBIT2 induces therapeutic fever through synchronized hypothalamic feedback, activating heat shock proteins, which are known to restore proteostasis and neuronal function. Case presentation: A 56-year-old woman was diagnosed with progressive ALS at the Mayo Clinic, with electromyography (EMG) demonstrating fibrillation and fasciculation indicative of denervation corroborated by neurological and MRI findings; the patient was informed that she had an expected survival of three to five years. A neurologist from Northwestern University confirmed the diagnosis and thus maintained the patient on FDA-approved ALS drugs (riluzole and edaravone). Her condition rapidly worsened despite pharmacological treatment, and she underwent CBIT2, resulting in (i) electrophysiological reversal with complete disappearance of denervation; (ii) biomarker correction, including reductions in neurofilament and homocysteine, IL-10 normalization (previously linked to mortality), and robust HSP70 induction; (iii) restoration of gait, swallowing, respiration, speech, and cognition; (iv) reconstitution of tongue structure; and (v) return to complex motor tasks, including golf, pickleball, and swimming. Discussion: This case provides the first documented evidence that ALS can be reversed through digitally reengineered fever therapy aligned with thermoregulation, which induces heat shock response and upregulates heat shock proteins, resulting in the patient no longer meeting diagnostic criteria for ALS and discontinuation of ALS-specific medications. Beyond ALS, shared protein-misfolding pathology suggests that CBIT2 may extend to Alzheimer’s, Parkinson’s, and related disorders. By modernizing this Nobel Prize-recognized therapeutic principle with computerized precision, CBIT2 establishes a framework for large-scale clinical trials. A century after fever therapy restored lost brain function and so decisively reversed dementia paralytica such that it earned the 1927 Nobel Prize in Medicine, CBIT2 now safely harnesses the therapeutic power of fever through noninvasive, intelligent, brain-guided thermal modulation. Amid a global brain health crisis, fever-based therapies may offer a path to preserve thought, memory, movement, and independence for the more than one-third of humanity currently affected by neurological disorders.